introduction to quantitative and targeted proteomic s
TRANSCRIPT
Introduction to Quantitative and Targeted Proteomics
Maciej LalowskiHiLIFE, Meilahti Clinical Proteomics Core Facility
University of Helsinki, FinlandFinnish Proteomics Society, President
Aalto University25.03.2019
1
Schematic representation of proteomic approaches
Gregorich, Z. R.; Chang, Y. H.; Ge, Y. Pflugers Archiv-European Journal of Physiology 2014, 466, 1199-12092
Schematic representation of quantitative proteomic approaches
Journal of Clinical and Translational Hepatology 2014 ;2(1): 23-303
Top-down: Two-dimensional gelelectrophoresis (2-DE)
• 1st dimension: IEF;Proteins areseparated accordingto their isoelectricpoint (IP)
• 2nd dimension: SDS-PAGE, Proteins areseparated accordingto their molecularweight
• Efficient: More than2000 proteinsresolved in E. Coli celllysates and ~8000 inbrain lysates
pH 10
SDS-
PAG
E
pH 3
4
pI 6.94.1
Mr(kDa)
200
15
About 2000 proteins
Phosphorylations?Glycosylations?Other types of PTMs?
Protein fingerprint (2-DE)
5
Protein quantitation (2D-DIGE)
6
2D-DIGE laboratory workflow
Bebek et al. J Nutritional Biochemistry 2014
7
Quantitate: pros and cons
© 2012 SlideShare Inc. 8
Plasma proteome challenge
Identification of 1,442 proteins in plasma that span more than 6logs of protein abundance as determined by mass spectral countsand independent assays of a subset of proteins identified in astudy of plasma from a pancreatic cancer mouse mode.
9
Mass spectrometry principles
Data Dependent AcquisitionData Independent AcquisitionSingle Reaction Monitoring
Fragmentation
Fragmentation
Fragmentation
Most abundant precursor ions
All precursor ions
Predefined precursor ionQ1 Q2 Q3
10
© 2012 SlideShare Inc. 11
SILAC- Stable isotope labeling with amino acids in cell culture
One of the cell populations is fed with growth medium containing normal amino acids (State A). In contrast, the second(third) population is fed with growth medium containing amino acids labeled with stable (non-radioactive)heavy isotopes (B-C). The medium can contain f.ex. Arg labeled with six 13C instead of the normal 12C or 2H4-lysine(Lys4). From ratios we calculate the relative protein abundance.
Geiger T, et al., Nature protocols (2011) . https://www.biochem.mpg.de/221777/SILAC 12
Different variants of SILAC for the analysis of cellularproteome dynamics
SILAC can be used to quantify differences in steady-state protein levels, measuredifferences in protein synthesis and reveal protein turnover (courtesy of M. Selbach, MDC).
13
Metabolic labeling
Drawbacks: unpredictable mass shifts induced by total 15N labeling14
iTRAQ-isobaric tags relative abundance quantitation
iTRAQ uses stable isotope labeled molecules that can be covalently bonded to theN-terminus and side chain amines of proteins. 4-, 8, 10- plex quantitiation
15
ICAT- isotope-coded affinity tags quantitation
ICAT reagent pairs are Cysteine-binding tags that differ in molecular weightby use of hydrogen or carbon isotopes
16
Enzymatic 18O label workflow
Pros:Ø Can apply to virtually any sample
type including clinical samples,Ø Peptides labeled by 16O and 18O co-
elute from the RP chromatographiccolumns which allows for accuratequantification,
Ø Amendable to low sampleconcentration
Cons:Ø Only 2 samples can be compared
to each other at one time,Ø Difficulty accommodating complex
experimental design,
http://proteomics.case.edu/proteomics/17
Overview of the label-free quantitative MS experimental workflow
Label-free quantitative proteomics can be divided into two approaches; spectral counting (SC) and AUCmeasurement (AUC). Spectral TIC combines features of both SC and AUC approaches.
Neilson KA et al, Proteomics 2011 Feb;11(4):535-53 18
Schematic representation of the two different label-freeapproaches
In the spectral-counting approach peptide and protein abundances can be estimated based onthe number of acquired peptide spectrum matches. In the ion-intensity-based approach thechanges of peptide abundances are determined by measuring and comparing thechromatographic peak areas of the corresponding peptides.
Megger DA et al, BBA 2013 Aug;1834(8):1581-90 19
TMT- tandem mass tags
The recent extension of TMT multiplexing to 10 conditions has beenenabled by utilizing neutron encoded tags with reporter ion m/z differences
of 0.0063 Da
Wu et al., Nature.2013, 499(7456):
79–82
20
CMT approach generates multiples reporter ion series forincreased quantitative information
Braun CR et al, Anal. Chem. , 2015, 87 (19), 9855–9863. 21
Peak intensity is the intensityat the highest point of the MS1peak for a peptideMS product ion abundance(MS2 intensities)
22
Mass spectrometry principles
Data Dependent AcquisitionData Independent AcquisitionSingle Reaction Monitoring
Fragmentation
Fragmentation
Fragmentation
Most abundant precursor ions
All precursor ions
Predefined precursor ionQ1 Q2 Q3
23
Courtesy of Bruno Domon 24
MRM analysis of Aß17-28 peptides from the brain
Analytical 2µm Acclaim PepMap RSLC C18, 75µm x 250mm column (Thermo™). Linear gradient of 3 to 35% of 0.1% FA/ACNon a QTRAP 6500+ (SCIEX™).
Four different labelling statuses of Ab17-28 peptide, i.e.unlabeled, Lys U-13C6; U-15N2, uniformly labelled 15N and Lys-13
can be detected.
25
Complementarity of unbiased and biased approaches tophosphoproteomics for understanding cell signal pathways
Stuart J. Cordwell, and Melanie Y. White Circulation. 2012;126:1803-1807
Copyright © American Heart Association, Inc. All rights reserved.
Ø Novel (N)Ø Known (K)Ø Abs against known
sites (W) ofPhosphorylation
Ø SRM/MRM usesunique precursorand fragment ionpairs (transitions)to specificallytarget peptidescontaining sites ofinterest (S) tocomplete pathwaymapping.
26
MRM in clinical medicine (examples)
Ø The quantification of proteins in the cerebrospinal fluid toaid understanding of the later stages of multiple sclerosis(26 markers of progressive MS)
Ø The development of quantitative validation techniquesfor plasma biomarkers (LOQ in low ng/ml, appropriate forserum biomarkers)
• The demonstration of robust targeted assays for cancerassociated protein quantification in both plasma andurine samples from patients (over 1,000 cancer-associated proteins in both serum and urine, confirmedELISA results for ApoA1, transferrin, β2-microglobulinand TTR)
27
Courtesy Christina Ludwig et al., TU Munich 28
Courtesy Christina Ludwig et al., TU Munich 29
Ø The mission of FinnProt
ØMake proteomics research readily available for the largescientific community in Finland,ØPromote research and education in proteomics and protein
chemistry (scholarshisps/organizing the events)ØAct as the official Finnish collaborative body to international
proteomics organizations (EuPA),
FinnProt was founded in 2004
Finnish Proteomics Society FinnProt
More info on FinnProt from http://www.finnprot.fi/
30